Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1965 2
1966 2
1967 4
1968 3
1969 2
1970 1
1971 1
1972 3
1974 8
1975 4
1976 2
1977 2
1978 8
1979 7
1980 4
1981 2
1982 3
1983 8
1984 5
1985 6
1986 8
1987 4
1988 12
1989 5
1990 7
1991 12
1992 5
1993 3
1994 11
1995 11
1996 17
1997 9
1998 8
1999 15
2000 16
2001 7
2002 6
2003 10
2004 22
2005 21
2006 22
2007 29
2008 43
2009 23
2010 25
2011 20
2012 23
2013 13
2014 22
2015 23
2016 25
2017 14
2018 22
2019 27
2020 33
2021 38
2022 36
2023 40
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

721 results

Results by year

Filters applied: . Clear all
Page 1
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K. Izutsu K, et al. Among authors: ishikawa j. Blood. 2023 Mar 9;141(10):1159-1168. doi: 10.1182/blood.2022016862. Blood. 2023. PMID: 36150143 Free PMC article. Clinical Trial.
Structure of the IscB-ωRNA ribonucleoprotein complex, the likely ancestor of CRISPR-Cas9.
Kato K, Okazaki S, Kannan S, Altae-Tran H, Esra Demircioglu F, Isayama Y, Ishikawa J, Fukuda M, Macrae RK, Nishizawa T, Makarova KS, Koonin EV, Zhang F, Nishimasu H. Kato K, et al. Among authors: ishikawa j. Nat Commun. 2022 Nov 7;13(1):6719. doi: 10.1038/s41467-022-34378-3. Nat Commun. 2022. PMID: 36344504 Free PMC article.
Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Kameda K, et al. Among authors: ishikawa j. Leukemia. 2022 May;36(5):1361-1370. doi: 10.1038/s41375-022-01545-w. Epub 2022 Mar 28. Leukemia. 2022. PMID: 35347237
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Fuji S, et al. Among authors: ishikawa j. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30. Br J Haematol. 2024. PMID: 38037468
721 results